1.Fletcher CD, Unni KK, Mertens F. Pathology and genetics of tumours of soft tissue and bone. World Health Organization classification of tumours. 2013.
2.Thway K, Fisher C. Histopathological diagnostic discrepancies in soft tissue tumours referred to a specialist centre. Sarcoma. 2009;2009.
3.Ray-Coquard I, Montesco M, Coindre J, Dei Tos A, Lurkin A, Ranchère-Vince D, et al. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Annals of oncology. 2012;23(9):2442-9.
4.Singer S, editor New diagnostic modalities in soft tissue sarcoma. Seminars in surgical oncology; 1999: Wiley Online Library.
5.Bovée JV, Hogendoorn PC. Molecular pathology of sarcomas: concepts and clinical implications. Virchows Archiv. 2010;456(2):193-9.
6.Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. International Journal of Cancer. 2006;119(12):2922-30.
7.Fletcher CD, Organization WH, Cancer IAfRo. WHO classification of tumours of soft tissue and bone: IARC press; 2013.
8.Kindblom L-G. Lipomatous tumors—how we have reached our present views, what controversies remain and why we still face diagnostic problems: a tribute to Dr Franz Enzinger. Advances in anatomic pathology. 2006;13(6):279-85.
9.Suurmeijer A, de Bruijn D, Geurts van Kessel A, Miettinen M. Synovial sarcoma. WHO Classification of Tumours of Soft Tissue and Bone Lyon: IARC. 2013:213-5.
10.Rieker RJ, Weitz J, Lehner B, Egerer G, Mueller A, Kasper B, et al. Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathways. Virchows Archiv. 2010;456(3):277-85.
11.Lewis JJ, Antonescu CR, Leung DH, Blumberg D, Healey JH, Woodruff JM, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. Journal of Clinical Oncology. 2000;18(10):2087-94.
12.Coindre JM, Pelmus M, Hostein I, Lussan C, Bui BN, Guillou L. Should molecular testing be required for diagnosing synovial sarcoma? Cancer. 2003;98(12):2700-7.
13.Guillou L, Coindre J-M, Gallagher G, Terrier P, Gebhard S, Somerhausen NDSA, et al. Detection of the synovial sarcoma translocation t (X; 18)(SYT; SSX) in paraffin-embedded tissues using reverse transcriptase-polymerase chain reaction: a reliable and powerful diagnostic tool for pathologists: a molecular analysis of 221 mesenchymal tumors fixed in different fixatives. Human pathology. 2001;32(1):105-12.
14.De Vreeze RS, de Jong D, Nederlof PM, Ariaens A, Tielen IH, Frenken L, et al. Added value of molecular biological analysis in diagnosis and clinical management of liposarcoma: a 30-year single-institution experience. Annals of surgical oncology. 2010;17(3):686-93.
15.Weaver J, Downs-Kelly E, Goldblum JR, Turner S, Kulkarni S, Tubbs RR, et al. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Modern Pathology. 2008;21(8):943-9.
16.Neuville A, Ranchère-Vince D, Dei Tos AP, Montesco MC, Hostein I, Toffolatti L, et al. Impact of molecular analysis on the final sarcoma diagnosis: a study on 763 cases collected during a European epidemiological study. The American journal of surgical pathology. 2013;37(8):1259-68.
17.Dei Tos AP, Doglioni C, Piccinin S, Sciot R, Furlanetto A, Boiocchi M, et al. Coordinated expression and amplification of the MDM2, CDK4, and HMGI‐C genes in atypical lipomatous tumours. The Journal of pathology. 2000;190(5):531-6.
18.Cho J, Lee SE, Choi Y-L. Diagnostic Value of MDM2 and DDIT3 Fluorescence In Situ Hybridization in Liposarcoma Classification: A Single-Institution Experience. Korean journal of pathology. 2012;46(2):115-22.
19.Sirvent N, Coindre J-M, Maire G, Hostein I, Keslair F, Guillou L, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. The American journal of surgical pathology. 2007;31(10):1476-89.
20.Saboorian MH, Ashfaq R, Vandersteenhoven JJ, Schneider NR. Cytogenetics as an adjunct in establishing a definitive diagnosis of synovial sarcoma by fine‐needle aspiration. Cancer Cytopathology. 1997;81(3):187-92.
21.Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT-SSX Fusion Type on the Clinical Behavior of Synovial Sarcoma A Multi-Institutional Retrospective Study of 243 Patients. Cancer research. 2002;62(1):135-40.
22.Surace C, Panagopoulos I, Pålsson E, Rocchi M, Mandahl N, Mertens F. A novel FISH assay for SS18–SSX fusion type in synovial sarcoma. Laboratory investigation. 2004;84(9):1185-92.
23.Ducimetière F, Lurkin A, Ranchère-Vince D, Decouvelaere A-V, Péoc'h M, Istier L, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PloS one. 2011;6(8):e20294.
24.Conyers R, Young S, Thomas DM. Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2010;2011.
25.Sreekantaiah C, Ladanyi M, Rodriguez E, Chaganti R. Chromosomal aberrations in soft tissue tumors. Relevance to diagnosis, classification, and molecular mechanisms. The American journal of pathology. 1994;144(6):1121.
26.Haldar M, Randall RL, Capecchi MR. Synovial sarcoma: from genetics to genetic-based animal modeling. Clinical orthopaedics and related research. 2008;466(9):2156-67.
27.Sugita S, Asanuma H, Hasegawa T. Diagnostic use of fluorescence in situ hybridization in expert review in a phase 2 study of trabectedin monotherapy in patients with advanced, translocation-related sarcoma. Diagnostic Pathology. 2016;11(1):1.
28.Thway K, Wang J, Swansbury J, Min T, Fisher C. Fluorescence in situ hybridization for MDM2 amplification as a routine ancillary diagnostic tool for suspected well-differentiated and dedifferentiated liposarcomas: experience at a tertiary center. Sarcoma. 2015;2015.
29.Italiano A, Di Mauro I, Rapp J, Pierron G, Auger N, Alberti L, et al. Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study. The Lancet Oncology. 2016;17(4):532-8.
How to Cite This Article:
|
30.Horn H, Allmanritter J, Doglioni C, Marx A, Müller J, Gattenlöhner S, et al. Fluorescence in situ analysis of soft tissue tumor associated genetic alterations in formalin-fixed paraffin-embedded tissue. Pathology-Research and Practice. 2014;210(12):804-11.
31.Guan Z, Yu X, Wang H, Zhang J, Cao J, Li G, et al. Advances in the targeted therapy of liposarcoma. Onco Targets Ther. 2015;8:125-36.